Genetic and Epigenetic Alterations in Bladder Cancer

被引：57

作者：

Li, Hong-Tao ^{[1
]}

Duymich, Christopher E. ^{[1
]}

Weisenberger, Daniel J. ^{[1
,2
]}

Liang, Gangning ^{[1
,3
]}

机构：

[1] Univ Southern Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA

[2] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Med, Los Angeles, CA 90089 USA

[3] Univ Southern Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90089 USA

来源：

INTERNATIONAL NEUROUROLOGY JOURNAL | 2016年 / 20卷

关键词：

Epigenetics; Genetic; Urinary Bladder Neoplasms; DNA Methylation; Epigenetic Therapy; TRANSITIONAL-CELL CARCINOMA; DNA METHYLATION PATTERNS; CPG ISLAND METHYLATION; URINE SEDIMENTS; UROTHELIAL CARCINOMA; TUMOR-SUPPRESSOR; BODY METHYLATION; GENOME; BIOMARKERS; MUTATIONS;

D O I：

10.5213/inj.1632752.376

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Bladder cancer is one of the most common cancers worldwide, with a high rate of recurrence and poor outcomes as a result of relapse. Bladder cancer patients require lifelong invasive monitoring and treatment, making bladder cancer one of the most expensive malignancies. Lines of evidence increasingly point to distinct genetic and epigenetic alteration patterns in bladder cancer, even between the different stages and grades of disease. In addition, genetic and epigenetic alterations have been demonstrated to play important roles during bladder tumorigenesis. This review will focus on bladder cancer-associated genomic and epigenomic alterations, which are common in bladder cancer and provide potential diagnostic markers and therapeutic targets for bladder cancer treatment.

引用

页码：84 / 94

页数：11

共 99 条

[1] Evaluation of the Methylation Status of Tumour Suppressor Genes for Predicting Bacillus Calmette-Guerin Response in Patients With T1G3 High-Risk Bladder Tumours [J].

Agundez, Miriam ;

Grau, Laura ;

Palou, Joan ;

Algaba, Ferran ;

Villavicencio, Humberto ;

Sanchez-Carbayo, Marta .

EUROPEAN UROLOGY, 2011, 60 (01) :131-140

[2]

American Cancer Society, 2016, CANC FACTS FIG 2016

[3]

[Anonymous], EUR UROL

[4]

[Anonymous], 2007, BIOL CANC

[5]

[Anonymous], 2016, SEER STAT FACT SHEET

[6]

Bakkar AA, 2003, CANCER RES, V63, P8108

[7] Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy [J].

Balbas-Martinez, Cristina ;

Sagrera, Ana ;

Carrillo-de-Santa-Pau, Enrique ;

Earl, Julie ;

Marquez, Mirari ;

Vazquez, Miguel ;

Lapi, Eleonora ;

Castro-Giner, Francesc ;

Beltran, Sergi ;

Bayes, Monica ;

Carrato, Alfredo ;

Cigudosa, Juan C. ;

Dominguez, Orlando ;

Gut, Marta ;

Herranz, Jesus ;

Juanpere, Nuria ;

Kogevinas, Manolis ;

Langa, Xavier ;

Lopez-Knowles, Elena ;

Lorente, Jose A. ;

Lloreta, Josep ;

Pisano, David G. ;

Richart, Laia ;

Rico, Daniel ;

Salgado, Rocio N. ;

Tardon, Adonina ;

Chanock, Stephen ;

Heath, Simon ;

Valencia, Alfonso ;

Losada, Ana ;

Gut, Ivo ;

Malats, Nuria ;

Real, Francisco X. .

NATURE GENETICS, 2013, 45 (12) :1464-U221

[8] Bladder cancer I.: Molecular and genetic basis of carcinogenesis [J].

Brandau, S ;

Böhle, A .

EUROPEAN UROLOGY, 2001, 39 (05) :491-497

[9] Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas [J].

Cappellen, D ;

De Oliveira, C ;

Ricol, D ;

de Medina, SGD ;

Bourdin, J ;

Sastre-Garau, X ;

Chopin, D ;

Thiery, JP ;

Radvanyi, F .

NATURE GENETICS, 1999, 23 (01) :18-20

[10] Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma [J].

Catto, JWF ;

Azzouzi, AR ;

Rehman, I ;

Feeley, KM ;

Cross, SS ;

Amira, N ;

Fromont, G ;

Sibony, M ;

Cussenot, O ;

Meuth, M ;

Hamdy, FC .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2903-2910

← 1 2 3 4 5 6 7 8 9 10 →